Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) CEO Sells $1,564,744.00 in Stock

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) CEO Peter Greenleaf sold 195,593 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $8.00, for a total value of $1,564,744.00. Following the completion of the sale, the chief executive officer now directly owns 1,953,892 shares of the company’s stock, valued at approximately $15,631,136. This represents a 9.10 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Aurinia Pharmaceuticals Stock Down 5.5 %

Shares of AUPH opened at $8.19 on Friday. The firm has a market cap of $1.17 billion, a P/E ratio of -54.60 and a beta of 1.22. The stock has a 50 day simple moving average of $8.10 and a two-hundred day simple moving average of $7.86. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11. Aurinia Pharmaceuticals Inc. has a 1 year low of $4.71 and a 1 year high of $10.67.

Analyst Upgrades and Downgrades

Separately, StockNews.com lowered Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 19th.

Institutional Trading of Aurinia Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Tang Capital Management LLC boosted its stake in shares of Aurinia Pharmaceuticals by 16.6% during the fourth quarter. Tang Capital Management LLC now owns 8,429,500 shares of the biotechnology company’s stock valued at $75,697,000 after purchasing an additional 1,200,000 shares during the period. State Street Corp boosted its stake in shares of Aurinia Pharmaceuticals by 2.3% during the third quarter. State Street Corp now owns 2,945,060 shares of the biotechnology company’s stock valued at $21,587,000 after purchasing an additional 64,949 shares during the period. Vanguard Group Inc. boosted its stake in shares of Aurinia Pharmaceuticals by 6.9% during the fourth quarter. Vanguard Group Inc. now owns 1,729,948 shares of the biotechnology company’s stock valued at $15,535,000 after purchasing an additional 112,113 shares during the period. Nuveen Asset Management LLC boosted its stake in shares of Aurinia Pharmaceuticals by 10.2% during the fourth quarter. Nuveen Asset Management LLC now owns 1,492,301 shares of the biotechnology company’s stock valued at $13,401,000 after purchasing an additional 138,054 shares during the period. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter valued at approximately $9,662,000. Hedge funds and other institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.